powered by Surfing Waves

Latest News

Racial and Ethnic Health Disparities Related to COVID-19

22 Jan 2021

One of the most disturbing aspects of the coronavirus disease 2019 (COVID-19) pandemic in the US is the disproportionate harm that it has caused to historically marginalized groups. Black, Hispanic, and Asian people have substantially higher rates of infection, hospitalization, and death compared with White people.

KFF COVID-19 Vaccine Monitor: January 2021

22 Jan 2021

The KFF COVID-19 Vaccine Monitor is an ongoing research project tracking the public’s attitudes and experiences with COVID-19 vaccinations. Using a combination of surveys and qualitative research, this project tracks the dynamic nature of public opinion as vaccine development and distribution unfold, including vaccine confidence and hesitancy, trusted messengers and messages, as well as the public’s experiences with vaccination.

Allergic Reactions Including Anaphylaxis After Receipt of the First Dose of Pfizer-BioNTech COVID-19 Vaccine

21 Jan 2021

On December 11, 2020, the US Food and Drug Administration (FDA) issued an Emergency Use Authorization (EUA) for the Pfizer-BioNTech coronavirus disease 2019 (COVID-19) vaccine, administered as 2 doses separated by 21 days.

Why a pioneering plan to distribute COVID vaccines equitably must succeed

13 Jan 2021

COVAX is key to both immunizing the world’s poorest people and ending the pandemic.

Science advisers: publish evidence behind COVID vaccine dosing strategy

12 Jan 2021

Countries that change established coronavirus vaccine schedules must be transparent, both to maintain public trust and so others can benefit from their knowledge.


11 clinical trials that will shape medicine in 2023

23 Dec 2023

2022 has been a rollercoaster year for biopharma, as it has faced an industry-wide slowdown and late-stage clinical trial failures, as well as breakthroughs and regulatory approvals. COVID-19 has continued to disrupt nearly all aspects of clinical trial infrastructure, from patient recruitment to supply chains, but despite this, 2023 promises to bring many new readouts from different branches of medicine (Table 1). Nature Medicine asked 11 leading experts for their top clinical trials to watch in the coming year

Association of Baseline Adherence to Antihypertensive Medications With Adherence After Shelter-in-Place Guidance for COVID-19 Among US Adults

20 Dec 2022

Question: Does baseline antihypertensive medication adherence identify individuals at risk for poor adherence during sheltering for COVID-19? Findings This cohort study assessed antihypertensive medication adherence as the proportion of days covered (PDC) from filled prescriptions claims for 6 months before and after COVID-19 sheltering guidance in a random sample of 27 318 US adults. Poor adherence (PDC < 50) during sheltering occurred in 73% with poor baseline adherence, 32% with fair baseline adherence (PDC 50-79), and 10% with good baseline adherence (PDC ≥ 80). These findings suggest that adherence-promoting interventions may be helpful irrespective of sheltering for poor baseline adherence and during sheltering for fair baseline adherence.

Changes in the Relationship Between Income and Life Expectancy Before and During the COVID-19 Pandemic, California, 2015-2021

07 Jul 2022

Key Points Question How did the first 2 years of the COVID-19 pandemic affect life expectancy in California and the relationship between census tract income and life expectancy relative to prepandemic years? Findings In this retrospective analysis of 1 988 606 deaths in California during 2015 to 2021, life expectancy declined from 81.40 years in 2019 to 79.20 years in 2020 and 78.37 years in 2021. Life expectancy differences between the census tracts in the highest and lowest income percentiles increased from 11.52 years in 2019 to 14.67 years in 2020 and 15.51 years in 2021. Meaning This ecological study of deaths in the state of California demonstrated that life expectancy declines in 2020 increased in 2021 and that the life expectancy gap by income level increased during the first 2 years of the COVID-19 pandemic relative to the pre-pandemic period.

Four Vaccine Doses Prevented Severe Omicron COVID-19 Better Than 3

10 May 2022

Older patients in Israel who received a fourth dose of the BNT162b2 (Pfizer-BioNTech) SARS-CoV-2 vaccine were more than 3 times less likely to develop severe COVID-19 than those who received only 3 doses. But while protection against severe disease did not wane during the testing period, protection against confirmed infection appeared short-lived.

Rates of COVID-19 Among Unvaccinated Adults With Prior COVID-19

20 Apr 2022

Risk of SARS-CoV-2 reinfection among unvaccinated people with prior COVID-19 is a subject of debate.1,2 We performed a survival analysis in a large US population to assess the degree and duration of protection associated with natural immunity in unvaccinated individuals.

Enroll for Free